TY - JOUR
T1 - NO and NO-independent mechanisms mediate ETB receptor buffering of ET-1-induced renal vasoconstriction in the rat
AU - Just, Armin
AU - Olson, Andrea J M
AU - Falck, J R
AU - Arendshorst, William J.
PY - 2005/5
Y1 - 2005/5
N2 - Vascular endothelin (ET) type B (ETB) receptors exert dilator and constrictor actions in a complex interaction with ETA receptors. We aimed to clarify the presence and relative importance of nitric oxide (NO) and other mechanisms underlying the dilator effects of ETB receptors in rat kidneys. Complete inhibition of NO production with Nω- nitro-L-arginine methyl ester (L-NAME, 25 mg/kg iv) enhanced the renal vasoconstriction elicited by ET-1 injected into the renal artery from -15 to -30%. Additional infusion of the NO donor nitroprusside (NP) into the renal artery did not reverse this effect (-29%) but effectively buffered ANG II-mediated vasoconstriction. Similarly, ET-1 responses were enhanced after a smaller intrarenal dose of L-NAME (-22 vs. -15%)and were unaffected by subsequent NP infusion (-21%). These results indicate that the responsiveness to ET-1 is buffered by ETB receptor-stimulated phasic release of NO, rather than its static mean level. Infusion of the ETB receptor antagonist BQ-788 into the renal artery further enhanced the ET-1 constrictor response to NP + L-NAME (-92 vs. -49%), revealing an NO-independent dilator component. In controls, vasoconstriction to ET-1 was unaffected by vehicle (-27 vs. -20%) and markedly enhanced by BQ-788 (-70%). The same pattern was observed when indomethacin (Indo) was used to inhibit cyclooxygenase (-20% for control, -22% with Indo, and -56% with ETB antagonist) or methylsulfonyl-6-(2- propargyloxyphenyl)-hexanamide (MS-PPOH) or miconazole + Indo was used to inhibit epoxygenase alone (-10% for control, -11% with MS-PPOH, and -35% with ETB antagonist) or in combination (-14% for control, -20% with Indo + miconazole, and -43% with ETB antagonist). We conclude that phasic release of NO, but not its static level, mediates part of the dilator effect of ETB receptors and that an NO-independent mechanism, distinct from prostanoids and epoxyeicosatetraenoic acids, perhaps ETB receptor clearance of ET-1, plays a major buffering role.
AB - Vascular endothelin (ET) type B (ETB) receptors exert dilator and constrictor actions in a complex interaction with ETA receptors. We aimed to clarify the presence and relative importance of nitric oxide (NO) and other mechanisms underlying the dilator effects of ETB receptors in rat kidneys. Complete inhibition of NO production with Nω- nitro-L-arginine methyl ester (L-NAME, 25 mg/kg iv) enhanced the renal vasoconstriction elicited by ET-1 injected into the renal artery from -15 to -30%. Additional infusion of the NO donor nitroprusside (NP) into the renal artery did not reverse this effect (-29%) but effectively buffered ANG II-mediated vasoconstriction. Similarly, ET-1 responses were enhanced after a smaller intrarenal dose of L-NAME (-22 vs. -15%)and were unaffected by subsequent NP infusion (-21%). These results indicate that the responsiveness to ET-1 is buffered by ETB receptor-stimulated phasic release of NO, rather than its static mean level. Infusion of the ETB receptor antagonist BQ-788 into the renal artery further enhanced the ET-1 constrictor response to NP + L-NAME (-92 vs. -49%), revealing an NO-independent dilator component. In controls, vasoconstriction to ET-1 was unaffected by vehicle (-27 vs. -20%) and markedly enhanced by BQ-788 (-70%). The same pattern was observed when indomethacin (Indo) was used to inhibit cyclooxygenase (-20% for control, -22% with Indo, and -56% with ETB antagonist) or methylsulfonyl-6-(2- propargyloxyphenyl)-hexanamide (MS-PPOH) or miconazole + Indo was used to inhibit epoxygenase alone (-10% for control, -11% with MS-PPOH, and -35% with ETB antagonist) or in combination (-14% for control, -20% with Indo + miconazole, and -43% with ETB antagonist). We conclude that phasic release of NO, but not its static level, mediates part of the dilator effect of ETB receptors and that an NO-independent mechanism, distinct from prostanoids and epoxyeicosatetraenoic acids, perhaps ETB receptor clearance of ET-1, plays a major buffering role.
KW - Angiotensin II
KW - Cyclooxygenase
KW - Dopamine
KW - Endothelial cell
KW - Endothelin
KW - Epoxygenase
KW - Nitric oxide
KW - Renal hemodynamics
UR - http://www.scopus.com/inward/record.url?scp=17844384204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844384204&partnerID=8YFLogxK
U2 - 10.1152/ajpregu.00550.2004
DO - 10.1152/ajpregu.00550.2004
M3 - Article
C2 - 15618347
AN - SCOPUS:17844384204
SN - 0363-6119
VL - 288
SP - R1168-R1177
JO - American Journal of Physiology - Regulatory Integrative and Comparative Physiology
JF - American Journal of Physiology - Regulatory Integrative and Comparative Physiology
IS - 5 57-5
ER -